Sanofi SA (SAN) PT Set at €82.00 by Goldman Sachs Group, Inc. (The)
Sanofi SA (EPA:SAN) has been given a €82.00 ($96.47) price objective by equities research analysts at Goldman Sachs Group, Inc. (The) in a research report issued to clients and investors on Friday. The firm presently has a “neutral” rating on the stock. Goldman Sachs Group, Inc. (The)’s price objective would suggest a potential upside of 3.77% from the stock’s previous close.
A number of other research firms have also recently commented on SAN. J P Morgan Chase & Co reissued a “neutral” rating and set a target price on shares of Sanofi SA in a research report on Friday, September 8th. Kepler Capital Markets set a €90.00 ($105.88) price target on shares of Sanofi SA and gave the company a “buy” rating in a report on Thursday, September 7th. BNP Paribas set a €83.00 ($97.65) price target on shares of Sanofi SA and gave the company a “neutral” rating in a report on Wednesday, September 6th. HSBC Holdings plc set a €81.00 ($95.29) price target on shares of Sanofi SA and gave the company a “neutral” rating in a report on Wednesday, August 30th. Finally, Jefferies Group LLC set a €87.00 ($102.35) price target on shares of Sanofi SA and gave the company a “neutral” rating in a report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of €87.24 ($102.63).
Sanofi SA (EPA SAN) opened at €79.02 ($92.96) on Friday. Sanofi SA has a 12-month low of €70.94 ($83.46) and a 12-month high of €92.97 ($109.38).
About Sanofi SA
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Stock Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related stocks with our FREE daily email newsletter.